TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06446206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab, paclitaxel, carboplatin, bevacizumab, fluzoparib
Description: Adebrelimab plus paclitaxel, carboplatin and bevacizumab induction therapy followed by maintenance therapy with adebrelimab plus fluzoparib and bevacizumab.
Study: NCT00012896

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Telephone Care + Educational (AV Materials)
Study: NCT05780346

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TGNB-CARE (Connecting and Reflecting Experience)
Description: 12 session 60-minute mentalizing-focused parenting group with approximately 6 caregivers, facilitated by a mental health clinician
Study: NCT06118346

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Female-Specific Cognitive Behavioral Therapy (FS-CBT)
Description: FS-CBT is a unique 12-session weekly group CBT treatment designed for women Veterans with AUD and/or risky drinking, and provides (1) AUD interventions, (2) general female-specific content, (3) female-Veteran content, (4) wellness and self-care, and (5) a novel 24/7 social support for abstinence discussion mobile app.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual care means that participants will receive brief alcohol counseling and have access to available treatments for AUD at the VA.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care means that participants will receive brief alcohol counseling and have access to available treatments for AUD at the VA.
Study: NCT05372874

Intervention type: DRUG
Intervention: Direct Acting Antivirals
Description: hepatitis C patients will be treated by direct acting antiviral drugs (DAAs)for 12 weeks.

Intervention type: DRUG
Intervention: Direct Acting Antivirals
Description: hepatitis C patients will be treated by direct acting antiviral drugs (DAAs)for 12 weeks.
Study: NCT06453512

Intervention type: DEVICE
Group type: OTHER
Intervention: Doublebase Once
Description: Emollient
Study: NCT05506722

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Testes shocker
Description: It is a device that give electric shocks (up to 5 milli Amperes) and it is designed to contain both the testes within it.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Testes shocker
Description: It is a device that give electric shocks (up to 5 milli Amperes) and it is designed to contain both the testes within it.
Study: NCT05329298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPI-361175
Description: Subjects will receive BPI-361175 until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPI-361175
Description: Subjects will receive BPI-361175 until disease progression
Study: NCT04785508

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: neuromuscolar tape
Description: neuromuscalar tape application in decompression technique (hand and arm)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: antigravity arm position
Description: antigravity arm position
Study: NCT05981248

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Intervention for Emotional Distress
Description: Mindfulness Intervention for Emotional Distress (MIED) program provide standard audio instructions for mindfulness exercises, introduce the nature and law of anxiety, depression and other emotions, the source of anxiety, depression and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
Study: NCT05368441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Patients of midazolam group will be treated with midazolam premedication (3 cc mixture of 0.1 mg/kg midazolam and normal saline; maximum midazolam dose, 3 mg) intravenously at waiting area 3 minutes before transportation to an operating room. In anesthesia induction, propofol 2 mg/kg will be given.Before the patients were given muscle relaxants, the patients were evaluated with the Han scale.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Control group patients are treated with 3 cc normal saline at waiting area 3 minutes before transportation to an operating room. In anesthesia induction, propofol 2 mg/kg will be given. Before the patients were given muscle relaxants, the patients were evaluated with the Han's grading scale.
Study: NCT06322797

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: In Sound Mode, no actual stimulation is applied, and 20 minutes of treatment is performed like other experimental groups.
Study: NCT05966220

Intervention type: DEVICE
Group type: OTHER
Intervention: Hip surgery with FH Ortho devices
Description: This study is a real-life observatory designed to collect long-term clinical data on patients who have undergone hip joint replacement or repair following hip trauma.~In this type of intervention, one or more medical devices distributed by FH ORTHO Company may be used by surgeons.

Intervention type: DEVICE
Group type: OTHER
Intervention: Hip surgery with FH Ortho devices
Description: This study is a real-life observatory designed to collect long-term clinical data on patients who have undergone hip joint replacement or repair following hip trauma.~In this type of intervention, one or more medical devices distributed by FH ORTHO Company may be used by surgeons.
Study: NCT05266820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: For the experimental group, the intervention was thalidomide（100mg PO Bid)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAS-102
Description: TAS-102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-102
Description: TAS-102
Study: NCT06097767

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine citrate
Description: It includes preterm infants with respiratory distress syndrome who received caffeine treatment as intravenous caffeinospire (Caffeine citrate) 60 mg / 3 ml (20 mg /ml) 3 ml vial for injection.
Study: NCT05366465

Intervention type: OTHER
Intervention: SMA adult patients
Description: An online questionnaire aimed at collecting demographic and social data, and data concerning activity limitations, participation and quality of life of SMA patients from validated scales : QOLNMD, Rosenberg.
Study: NCT04781036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4%Chlorhexidine
Description: 4%Chlorhexidine was given to participants with foot odor for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4%Chlorhexidine
Description: 4%Chlorhexidine was given to participants with foot odor for 2 weeks
Study: NCT03814941

Intervention type: OTHER
Intervention: paper-based anesthesia record
Description: to evaluate the incidence of artifacts in the AIMS database by paper-based anesthesia record

Intervention type: OTHER
Intervention: electronic documents
Description: to evaluate the incidence of artifacts in the AIMS database by electronic documents anesthesia record
Study: NCT06097767

Intervention type: DRUG
Group type: OTHER
Intervention: Amikacin
Description: it includes preterm infants with respiratory distress syndrome who received amikacin in regular intervention therapy in control group
Study: NCT02925806

Intervention type: OTHER
Intervention: Non-interventional study - retrospective database review

Intervention type: OTHER
Intervention: Non-interventional study - retrospective database review

Intervention type: OTHER
Intervention: Non-interventional study - retrospective database review

Intervention type: OTHER
Intervention: Non-interventional study - retrospective database review
Study: NCT05667350

Intervention type: OTHER
Intervention: Blood drawing
Description: Blood drawing before anti-cancer therapy

Intervention type: OTHER
Intervention: Blood drawing
Description: Blood drawing before radical treatment
Study: NCT06370039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INV-102
Description: INV-102 Ophthalmic Solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle Ophthalmic Solution
Study: NCT04933526

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flumatinib
Description: Flumatinib 600mg QD orally form 1 to 12 months
Study: NCT04608877

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Take 5 and Audio Clip
Description: Parent will receive the 5 discrete safety steps for infant crying and listen to the audio clip of infant crying and public service announcement message

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Take 5 Only
Description: Parent will only receive the 5 discrete safety steps for infant crying
Study: NCT04339270

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithropycin according to symptoms
Description: Patients randomized to the standardized comparator arm will benefit from the standard treatment for COPD, including with regard to the prescription of azithromycin in case of severe sputum complaints (here defined by a CASA-Q sputum symptoms score \<70 to homogenize practices between centers).~CASA-Q will be evaluated every 3 months.~* If the patient has a sputum symptoms score \<70, a prescription for 3 months of azithromycin treatment will be initiated. This prescription can be renewed every 3 months during the 12 months of follow-up planned in this study, if the patient continues to obtain a sputum symptoms score \<70.~* If the patient has a sputum symptoms score\> 70, management is not changed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin according to rheology or symptoms
Description: Treatment according to standard COPD management, except for the prescription of azithromycin, which will be prescribed in function of mucus rheology or as a function of sputum complaints (here defined by a CASA-Q sputum symptoms score \<70).~The rheology of mucus will be quantified every 3 months.~* If the patient has spontaneous or induced sputum, and this sputum has a critical constraint (tau-C) \> 39, a prescription for 3 months of azithromycin treatment will be initiated. This prescription may be renewed every 3 months during the 12 months of follow-up planned in this study.~* If the patient has a sputum symptoms score \<70, a prescription for 3 months of azithromycin treatment will be initiated. This prescription can be renewed every 3 months during the 12 months of follow-up planned in this study, if the patient continues to obtain a sputum symptoms score \<70.~* If the patient has a sputum symptoms score\> 70, management is not changed.
Study: NCT05983094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Utidelone
Description: Utidelone injection 30mg/m2, on days 1-5 of each cycle
Study: NCT04933526

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dasatinib
Description: Dasatinib 100mg QD orally form 1 to 12 months
Study: NCT05983094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Utidelone
Description: Utidelone injection 30mg/m2, on days 1-5 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Utidelone
Description: Utidelone injection 30mg/m2, on days 1-5 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin Area under curve(AUC)6, iv, was administered on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin Area under curve(AUC)6, iv, was administered on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Epirubicin 75mg/m2 was administered on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab 8mg/kg iv in first cycle on day 1, then 6mg/kg in the rest cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Pertuzumab 840mg/kg iv in first cycle on day 1, then 420mg/kg in the rest cycles
Study: NCT04884607

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: subthreshold low-level autonomic nerve stimulation using external auditory canal electrodes
Description: * Evaluation of electrocardiogram measurement from external auditory canal electrodes: Participants are required to attach specially designed external auditory canal electrodes to their both ears to record electrocardiogram. Both electrocardiogram from the precordium and the ear would be simultaneously recorded and compared.~* Evaluation of low-level autonomic nerve stimulation using external auditory canal: Using the electrodes described above, Arnold's nerve will be stimulated with low-level electric impulses using TENS device. During and after the stimulation, heart rate variability will be measured to investigate the impact of nerve stimulation on autonomic function modulation on the heart.
Study: NCT05203380

Intervention type: DRUG
Intervention: dupilumab
Description: Weight based dosing for 16 weeks in accordance of United States prescribing information (USPI)
Study: NCT03940807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11.25mg GnRH agonist
Description: Ultra-long protocol group women will receive one intra-muscular administration of 11.25 mg GnRH agonist (triptorelin acetate) on the luteal phase of their menstrual cycle. Ovarian stimulation will be started after 90 days desensitization.~After the desensitization period, all patients will undergo standardized ovarian stimulation, follicular aspiration, fertilization of all oocytes using either standard insemination or ICSI according to the features of sperm examination, fresh embryo transfer and luteal phase support.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.1 mg GnRH agonist
Description: Long protocol group women will receive a 15-days pituitary down-regulation protocol that consists of daily subcutaneous injection of 0.1mg of GnRH agonist (triptorelin acetate) started on the luteal phase of their menstrual cycle.~Ovarian stimulation will begin after 15 days desensitization. After the desensitization period, all patients will undergo standardized ovarian stimulation, follicular aspiration, fertilization of all oocytes using either standard insemination or ICSI according to the features of sperm examination, fresh embryo transfer and luteal phase support.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25 µg transdermal oestradiol
Description: Add back therapy (transdermal estradiol, 25μg twice a week) will be administrated throughout down-regulation period.
Study: NCT05533255

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional composite resin (3M™ Filtek™ Z350 XT Universal Restorative)
Description: Composite resin at room temperature is used.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preheated composite resin (3M™ Filtek™ Z350 XT Universal Restorative)
Description: Conventional composite resin (3M™ Filtek™ Z350 XT Universal Restorative) is preheated to a temperature of 57 degrees Celsius using a composite warmer for 10 minutes is used.
Study: NCT05711199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glyceroltrinitrat
Description: transdermal patch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glyceroltrinitrat
Description: transdermal patch
Study: NCT05577091

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Inverse correlated dual-target, truncated IL7Ra modified CAR -expressing autologous T-lymphocytes.
Description: Intratumoral or intraventricular administration via Ommaya reservoir.~Dose level 0: 1×10\^7 autologous Tris-CAR-T cells, at least one dose, maximum 6 doses, 2 patients.~Dose level 1: 1×10\^8/ 5×10\^6 autologous Tris-CAR-T cells, at least one dose, maximum 6 doses, 2 patients. The dose of Dose level 1 will refer to the adverse effect of Dose level 0. When dose-related side effects occurred in 2 patients in the Dose level 0, the dose should be reduced to 5×10\^6 cells.~In Dose levels 0 and 1, the second dose will be infused 28 days after the first dose, and the subsequent doses will be administered weekly.~Dose level 2: 5×10\^7 autologous Tris-CAR-T cells, weekly administered, maximum 8 weeks, 4 patients. If the results of Dose levels 0 and 1 suggested that dose-related toxic side effects could have occurred in the 1×10\^7cells dose, the researcher would re-determine the dosage of the multidose clinical exploration study.
Study: NCT06452693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQA3038 injection/placebo
Description: TQA3038 is a Anti-Hepatitis B virus (HBV) drugs.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nucleotide drugs Control group
Description: Nucleotide drugs are nucleoside reverse transcriptase inhibitors.
Study: NCT05831618

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interactive Visuo-Vestibular training
Description: Dynamic motor activitites aimed to enhance the visuo-vestibular interaction and the sensorial reweighting will be performed for the Interactive Visuo-Vestibular training group.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vestibular rehabilitation training
Description: Dynamic motor activitites aimed to enhance vestibular reflexes will be performed for the vestibular rehabilitation group
Study: NCT04831671

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Approach - Infra-patella nailing
Description: The intra-medullary nail will be introduced via an infra-patella incision.
Study: NCT05072665

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HIGH ECHOENDOSCOPY WITH THE FAST PROCEDURE
Description: HIGH ECHOENDOSCOPY WITH THE FAST PROCEDURE
Study: NCT05191342

Intervention type: DIAGNOSTIC_TEST
Intervention: Enzyme-linked immunosorbent assay for PCSK9
Description: Enzyme-linked immunosorbent assay for plasma PCSK9

Intervention type: DIAGNOSTIC_TEST
Intervention: Enzyme-linked immunosorbent assay for PCSK9
Description: Enzyme-linked immunosorbent assay for plasma PCSK9
Study: NCT04831671

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surgical Approach - Supra-patella nailing
Description: The intra-medullary nail will be introduced via a supra-patella incision.
Study: NCT06127433

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: Insulin Glargine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Dapagliflozin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin aspart
Description: Insulin aspart
Study: NCT04946695

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telefisio India
Description: Implement telephysiotherapy programmes in low-resource areas.
Study: NCT05909748

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GEMINUS Transcatheter Aortic Valve Implantation system
Description: Implantation of the GEMINUS Transcatheter Aortic Valve Implantation system
Study: NCT05855018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine sulfate eye drops
Description: One drop once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine sulfate eye drops
Description: One drop once daily
Study: NCT05941169

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytoreductive Nephrectomy
Description: The experimental intervention consists of cytoreductive nephrectomy (CN) or any ablative local therapy within 6 months and 1 year after start of systemic treatment. All types of ablative local therapy are allowed as a substitute for CN
Study: NCT05855018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine sulfate eye drops
Description: One drop once daily
Study: NCT05391568

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Real Dry Needling
Description: Needle will be placed at trapezius muscle. Fast-in, Fast-out technique will be used at the active trigger point of upper trapezius muscle.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Dry Needling
Description: Sham needle will be placed at trapezius muscle. Simulated Fast-in, Fast-out technique will be used at the active trigger point of upper trapezius muscle.
Study: NCT06366295

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: subgingival mechanotherapy with perioscopy
Description: Subgingival mechanotherapy using a machine scaler, curettes and a perioscope

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: classical subgingival mechanotherapy
Description: Subgingival mechanotherapy using a machine scaler and curettes
Study: NCT05768425

Intervention type: DIAGNOSTIC_TEST
Intervention: Real-time quaking-induced conversion (RT-QuIC)
Description: RT-QuIC measures the ability of alpha-synuclein (aSyn) to misfold other aSyn proteins and is an amplification technique.

Intervention type: DIAGNOSTIC_TEST
Intervention: Real-time quaking-induced conversion (RT-QuIC)
Description: RT-QuIC measures the ability of alpha-synuclein (aSyn) to misfold other aSyn proteins and is an amplification technique.

Intervention type: DIAGNOSTIC_TEST
Intervention: Real-time quaking-induced conversion (RT-QuIC)
Description: RT-QuIC measures the ability of alpha-synuclein (aSyn) to misfold other aSyn proteins and is an amplification technique.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cognitive test
Description: Minimal Mental State examination (MMSE), Montreal Cognitive Assessment (MoCA)
Study: NCT04416113

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: photobiomodulation and photodynamic therapy
Description: antiviral treatment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: photobiomodulation and photodynamic therapy
Description: antiviral treatment
Study: NCT05768425

Intervention type: DIAGNOSTIC_TEST
Intervention: Cognitive test
Description: Minimal Mental State examination (MMSE), Montreal Cognitive Assessment (MoCA)

Intervention type: DIAGNOSTIC_TEST
Intervention: Cognitive test
Description: Minimal Mental State examination (MMSE), Montreal Cognitive Assessment (MoCA)
Study: NCT04416113

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: photobiomodulation and photodynamic therapy
Description: antiviral treatment
Study: NCT05927987

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem Management Plus (PM+)
Description: Problem Management Plus (PM+) is a brief, psychological intervention program based on cognitive behavioural therapy (CBT) techniques that are empirically supported and formally recommended by the WHO (Dua et al., 2011; Tol et al., 2013). The full protocol was developed by the WHO and the University of New South Wales, Australia. The manual involves the following empirically supported elements: problem-solving, stress management, behavioural activation, and accessing social support. PM+ has three core features. It is brief (five sessions given in five weeks), delivered by paraprofessionals (PM+ helpers) and transdiagnostic. The PM+ helpers will be supervised by mental health care specialists.
Study: NCT06521216

Intervention type: DRUG
Intervention: Ferrous sulfate
Description: all patients will receive 200 mg elemental iron (ferrous sulphate)

Intervention type: DRUG
Intervention: Ferrous sulfate
Description: all patients will receive 200 mg elemental iron (ferrous sulphate)

Intervention type: DRUG
Intervention: Ferrous sulfate
Description: all patients will receive 200 mg elemental iron (ferrous sulphate)